Loading news article.

FilingSEC EDGAR424B3

Kazia Therapeutics Announces First Patient Dosed in Phase 1b/2a Trial of Paxalisib

Sep 22, 2026, 08:02 ET · SEC accepted

StagePhase 1b/2a

Filing content

The company announced that its partner has dosed the first patient in a Phase 1b/2a trial of Paxalisib for rare seizure disorders.

AI summary of the filing. Please also check the source.

Preparing English content…

Loading comments…